scholarly journals Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

2001 ◽  
Vol 345 (12) ◽  
pp. 851-860 ◽  
Author(s):  
Edmund J. Lewis ◽  
Lawrence G. Hunsicker ◽  
William R. Clarke ◽  
Tomas Berl ◽  
Marc A. Pohl ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Antagonist ◽  
Angiotensin Receptor ◽  
Angiotensin Receptor Antagonist ◽  
Renoprotective Effect

scholarly journals Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I

2006 ◽  
Vol 155 (2) ◽  
pp. 293-296 ◽  
Author(s):  
Adrienne A M Zandbergen ◽  
Steven W J Lamberts ◽  
Joop A M J L Janssen ◽  
Aart H Bootsma
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Fasting Glucose ◽  
Serum Levels ◽  
Model Assessment ◽  
Angiotensin Receptor ◽  
Angiotensin Receptor Antagonist ◽  
Igf I ◽  
Igfbp 3

Objective: Blocking the renin–angiotensin system (RAS) may reduce the risk of developing type-2 diabetes, but data are inconclusive and the mechanisms involved are unclear. RAS and RAS inhibition also influence the IGF-I system, which is important in glucose homeostasis. We investigated the effects of the angiotensin-receptor antagonist, losartan, on insulin resistance and IGF-I levels Design and methods: In this hypothesis-generating study, five individuals with impaired fasting glucose received 100 mg losartan during 8 weeks. Before and after the treatment period, insulin sensitivity was assessed using the homeostasis model assessment of insulin resistance (HOMA), as well as the 2-h continuous infusion of glucose with model assessment (CIGMA). Furthermore, serum levels of free and total IGF-I, IGF-binding protein-3 (IGFBP-3), lipids and HbAlc were measured. Results: After the treatment period, the HOMA score for insulin resistance had decreased from 5.3 ± 1.1 to 3.7 ± 0.9 (P = 0.004) and the 2-h CIGMA score from 23.4 ± 3.1 to 15.9 ± 2.1 (P = 0.07). The serum levels of free IGF-I had increased from 57 ± 18.8 to 134 ± 31.3 pmol/l (P = 0.04). In terms of percentage, the decrease of HOMA correlated with the increase in free IGF-I levels (Pearson’s correlation coefficient r = −0.8; P = 0.07). A trend in the same direction was observed with 2-h CIGMA. No differences were observed in lipids, total IGF-I, IGFBP-3 or HbAlc. Conclusions: Losartan raised serum levels of free IGF-I, which might contribute to the improvement of insulin resistance associated with losartan treatment. These observations, if confirmed in broader studies, will help our understanding of the pathogenesis of type-2 diabetes mellitus, as well as the role of angiotensin-receptor antagonists in its prevention.

scholarly journals Renal Effects of S18886 (Terutroban), a TP Receptor Antagonist, in an Experimental Model of Type 2 Diabetes

Diabetes ◽  
2007 ◽  
Vol 56 (4) ◽  
pp. 968-974 ◽  
Author(s):  
K. Sebekova ◽  
T. Eifert ◽  
A. Klassen ◽  
A. Heidland ◽  
K. Amann
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Antagonist ◽  
Experimental Model ◽  
Renal Effects ◽  
Tp Receptor

scholarly journals The Mineralocorticoid Receptor Antagonist Eplerenone Suppress Interstitial Fibrosis in Subcutaneous Adipose Tissue in Type 2 Diabetes Patients

2020 ◽  
Author(s):  
Ada Admin ◽  
Marie Louise Johansen ◽  
Jaime Ibarrola ◽  
Amaya Fernández-Celis ◽  
Morten Schou ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Adipose Tissue ◽  
Receptor Antagonist ◽  
Subcutaneous Adipose Tissue ◽  
Mineralocorticoid Receptor ◽  
Prostaglandin D2 ◽  
Type I ◽  
Mineralocorticoid Receptor Antagonist ◽  
Subcutaneous Adipose

Activation of the mineralocorticoid receptor (MR) may promote dysfunctional adipose tissue in patients with type 2 diabetes, where increased pericellular fibrosis has emerged as a major contributor. The knowledge of the association between the MR, fibrosis and the effects of an MR antagonist (MRA) in human adipocytes remains very limited. The present sub-study including 30 participants was prespecified as part of the Mineralocorticoid Receptor Antagonist in type 2 Diabetes (MIRAD) trial, randomizing patients to either high dose eplerenone or placebo for 26 weeks. In adipose tissue biopsies, changes in fibrosis were evaluated by immunohistological examinations and by the expression of mRNA and protein markers of fibrosis. Treatment with an MRA reduced pericellular fibrosis, synthesis of the major subunits of collagen type I and VI, and the profibrotic factor α-smooth muscle actin, as compared to placebo in subcutaneous adipose tissue. Furthermore, we found decreased expression of the MR and downstream molecules neutrophil gelatinase–associated lipocalin, galectin-3, and lipocalin-like prostaglandin D2 synthase with an MRA. In conclusions, we present original data demonstrating reduced fibrosis in adipose tissue with inhibition of the MR, which could be a potential therapeutic approach to prevent the extracellular matrix remodeling of adipose tissue in type 2 diabetes.

scholarly journals Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

2017 ◽  
Vol 19 (11) ◽  
pp. 1521-1528 ◽  
Author(s):  
Cristina B. Guzman ◽  
Xiaotian M. Zhang ◽  
Rong Liu ◽  
Arie Regev ◽  
Sudha Shankar ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Antagonist ◽  
Liver Fat ◽  
Glucagon Receptor ◽  
Glucagon Receptor Antagonist
Sign in / Sign up

Export Citation Format

Share Document